Single institutional experience of bladder-preserving trimodality treatment for muscle-invasive bladder cancer

Journal of Korean Medical Science

Volumn 23, Issue 4, 2008, Pages 598-603

  Jae, Young Joung ^a   Kyung, Seok Han ^a   Taek, Sang Kim ^a   Ho, Kyung Seo ^a   Chung, Jinsoo ^a   Kang, Hyun Lee ^a  

^a National Cancer Center   (South Korea)

Author keywords

Cisplatin; Combined modality treatment; Urinary bladder neoplasms

Indexed keywords

CISPLATIN;

ARTICLE; BLADDER TUMOR; CANCER INVASION; FEMALE; HUMAN; MALE; MORTALITY; MULTIMODALITY CANCER THERAPY; MUSCLE TUMOR; PATHOLOGY; SALVAGE THERAPY;

CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MUSCLE NEOPLASMS; NEOPLASM INVASIVENESS; SALVAGE THERAPY; URINARY BLADDER NEOPLASMS;

EID: 50449107925     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2008.23.4.598     Document Type: Article

References (24)

1. Shipley WU, Prout GR JR, Einstein AB, Coombs LJ, Wajsman Z, Soloway MS, Englander L, Barton BA, Hafermann MD. Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. JAMA 1987; 258: 931-5.
2. Housset M, Maulard C, Chretien Y, Dufour B, Delanian S, Huart J, Colardelle F, Brunel P, Baillet F. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder; a prospective study. J Clin Oncol 1993; 11: 2150-7.
3. Sauer R, Dunst J, Altendorf-Hofmann A, Fischer H, Bornhof C, Schrott KM. Radiotherapy with and without cisplatin in bladder cancer. Int J Radiat Oncol Biol Phys 1990; 19: 687-91.
4. Kachnic LA, Kaufman DS, Heney NM, Althausen AF, Griffin PP, Zietman AL, Shipley WU. Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol 1997; 15: 1022-9.
5. Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI, Herr H, Higgins G, Boyle MG. Long term survival in metastatic transitional cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999; 17: 3173-81.
6. Gospodarowicz MK, Warde P. The role of radiation therapy in the management of transitional cell carcinoma of the bladder. Hematol Oncol Clin North Am 1992; 6: 147-68.
7. Rodel C, Weiss C, Sauer R. Trimodality treatment and selective organ preservation for bladder cancer. J Clin Oncol 2006; 24: 5536-44.
8. Weiss C, Engehausen DG, Krause FS, Papadopoulos T, Dunst J, Sauer R, Rodel C. Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer. Int J Radiat Oncol Biol Phys 2007; 68: 1072-80.
9. Sangar VK, McBain CA, Lyons J, Ramani VA, Logue JP, Wylie JP, Clarke NW, Cowan RA. Phase I study of conformal radiotherapy with concurrent gemcitabine in locally advanced bladder cancer. Int J Radiat Oncol Biol Phys 2005; 61: 420-5.
10. Varveris H, Delakas D, Anezinis P, Haldeopoulos D, Mazonakis M, Damilakis J, Metaxaris G, Chondros N, Mavromanolakis E, Daskalopoulos G, Dimitrakopoulos A, Kranidis A. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell carcinoma: a preliminary report of tolerance and local control. Anticancer Res 1997; 17: 4771-80.
11. Nichols RC Jr, Sweetser MG, Mahmood SK, Malamud FC, Dunn NP, Adams JP, Kyker JS, Lydick K. Radiation therapy and concomitant palcitaxel/carboplatin chemotherapy for muscle invasive transitional cell carcinoma of the bladder: a well tolerated condition. Int J Cancer 2000; 90: 281-6.
12. Cohen-Jonathan E, Muschel RJ, Gillies McKenna W, Evans SM, Cerniglia G, Mick R, Kusewitt D, Sebti SM, Hamilton AD, Oliff A, Kohl N, Gibbs JB, Bernhard EJ. Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS. Radiat Res 2000; 154: 125-32.
13. Chakravarti A, Winter K, Wu CL, Kaufman D, Hammond E, Parliament M, Tester W, Hagan M, Grignon D, Heney N, Pollack A, Sandler H, Shipley W. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2005; 62: 309-17.
14. Rodel C, Grabenbauer GG, Kuhn R, Papadopoulos T, Dunst J, Meyer M, Schrott KM, Sauer R. Combined-modality treatment and selective organ preservation in invasive bladder cancer: Long-term results. J Clin Oncol 2002; 20: 3061-71.
15. Dunst J, Diestelhorst A, Kuhn R, Muller AC, Scholz HJ, Fornara P. Organ-sparing treatment in muscle-invasive bladder cancer. Strahlenther Onkol 2005; 181: 632-7.
16. Danesi DT, Arcangeli G, Cruciani E, Altavista P, Mecozzi A, Saracino B, Orefici F. Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results. Cancer 2004; 101: 2540-8.
17. Osen I, Fossa SD, Majak B, Rotterud R, Berner A. Prognostic factors in muscle-invasive bladder cancer treated with radiotherapy: an immunohistochemical study. Br J Urol 1998; 81: 862-9.
18. Rodel C, Grabenbauer GG, Rodel F, Birkenhake S, Kuhn R, Martus P, Zorcher T, Fursich D, Papadopoulos T, Dunst J, Schrott KM, Sauer R. Apoptosis, p53, bcl-2, and Ki-67 in invasive bladder carcinoma: possible predictors for response to radiochemotherapy and successful bladder preservation. Int J Radiat Oncol Biol Phys 2000; 46: 1213-21.
19. Pollack A, Wu CS, Czerniak B, Zagars GK, Benedict WF, McDonnell TJ. Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer. Clin Cancer Res 1997; 3: 1823-9.
20. Zietman AL, Shipley WU, Kaufman DS, Zehr EM, Heney NM, Althausen AF, McGovern FJ. A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer. J Urol 1998; 150: 1673-7.
21. Kaufman DS, Winter KA, Shipley WU, Heney NM, Chetner MP, Souhami L, Zlotecki RA, Sause WT, True LD. The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist 2000; 5: 471-6.
22. Hagan MP, Winter KA, Kaufman DS, Wajsman Z, Zietman AL, Heney NM, Toonkel LM, Jones CU, Roberts JD, Shipley WU. RTOG 97-06: Initial report of a phase I-II trial of selective bladder conservation using TURBT, twice daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys 2003; 57: 665-72.
23. Shipley WU, Kaufman DS, Zehr E, Heney NM, Lane SC, Thakral HK, Althausen AF, Zietman AL. Selective bladder preservation by combined modality protocol treatment: Long-term outcomes of 190 patients with invasive bladder cancer. Urology 2002; 60: 62-8.
24. Dalbagni G, Genega E, Hashibe M, Zhang ZF, Russo P, Herr H, Reuter V. Cystectomy for bladder cancer: a contemporary series. J Urol 2001; 165: 1111-6.